In Europe around 60 million people suffer from Diabetes Mellitus (DM) and in the Netherlands this number is around 1.2 million. About 90% of these suffer from Type 2 Diabetes Mellitus (T2DM) and 10% from Type 1 Diabetes Mellitus (T1DM). The prevalence of T2DM is increasing among all ages, mostly due to obesity, unhealthy diet and physical inactivity. Costs related to DM are high; around €95 billion in the EU and €1.6 billion in the Netherlands. Despite control by medication and attempting healthy lifestyle behaviors, lots of patients do have frequent episodes of hypoglycemia and hyperglycemia which significant impacts their well-being, quality of life and societal participation and which increases the risk of acute and long-term complications like nephropathy, macro- and microvascular diseases and neuropathy. Most patients with DM are being supervised by their general practitioner and in case of a more complex clinical picture by a team of medical specialists from the hospital. For this, patients regularly visit a health professional to check their blood glucose value, medication setting, whether complications do arise or to treat complications. With the rising capacity of patients with DM and limited financial resources proper care for these patients with DM is under pressure. Diabetes on Return aims to contribute to better diabetes management support. This program develops, evaluates and implements novel technologies to enable personalized diabetes management for patients with type 1 and 2 DM from in their own daily environment. Technologies like sensor systems for monitoring preclinical signs of complications and monitoring daily life behaviors, methods and tools for data analytics for dynamic phenothyping and tipping point analysis, new transparent prediction modelling tools for insulin supply and feedback control strategies for insulin delivery via pumps. In addition self-management support tools and persuasive 24/7 behavioural change techniques will be developed to support patients to return DM, prevent progression or development of complications. Diabetes on Return enables the society to make a shift from treatment to prevention, resulting in a significant reduction of care demands and costs.
The programme is led by research groups from the University of Twente, Radboudumc, Radboud University, Wageningen University and Research and University of Eindhoven, with TNO involved as one of the partners.
For more information, questions or to show your interest in joining the programme, please contact prof. dr. Miriam Vollenbroek-Hutten (University of Twente, e-mail: email@example.com).